[go: up one dir, main page]

MX385144B - Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata. - Google Patents

Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.

Info

Publication number
MX385144B
MX385144B MX2017014184A MX2017014184A MX385144B MX 385144 B MX385144 B MX 385144B MX 2017014184 A MX2017014184 A MX 2017014184A MX 2017014184 A MX2017014184 A MX 2017014184A MX 385144 B MX385144 B MX 385144B
Authority
MX
Mexico
Prior art keywords
prostate cancer
antibody
treatment
integrin alpha
relates
Prior art date
Application number
MX2017014184A
Other languages
English (en)
Inventor
Axel Hoffmann
Benoit Destenaves
Frederic Christian Pipp
Heinrich Lannert
Juergen Reindl
Karin Groll
Klaus Brischwein
Michael Zuehlsdorf
Otmar Pfaff
Sabine Raab
Ulrike Dau
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX385144B publication Critical patent/MX385144B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al tratamiento del cáncer de próstata por medio de anticuerpos. Ante todo, la invención se refiere a la administración de un anticuerpo anti-integrina alfa v (receptor) a pacientes que sufren de cáncer de próstata, especialmente cáncer de próstata resistente a la castración (CRPC), acompañado opcionalmente por metástasis en los ganglios linfáticos y huesos (mCRPC). En particular, la invención se refiere a la terapia de los pacientes por medio del anticuerpo anti-angiogénico DI17E6 y mutantes estructurales del mismo.
MX2017014184A 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata. MX385144B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11001135 2011-02-11
PCT/EP2012/000548 WO2012107211A1 (en) 2011-02-11 2012-02-07 Anti-alpha-v integrin antibody for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
MX385144B true MX385144B (es) 2025-03-14

Family

ID=45569571

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014184A MX385144B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.
MX2013009062A MX352025B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013009062A MX352025B (es) 2011-02-11 2012-02-07 Anticuerpo anti-integrina alfa v para el tratamiento de cancer de prostata.

Country Status (23)

Country Link
US (3) US9555110B2 (es)
EP (2) EP3415162A1 (es)
JP (2) JP6320042B2 (es)
KR (2) KR102103701B1 (es)
CN (1) CN103347540B (es)
AU (2) AU2012216145B2 (es)
CA (1) CA2827052C (es)
DK (1) DK2672994T3 (es)
EA (1) EA032117B1 (es)
ES (1) ES2683347T3 (es)
HR (1) HRP20181212T1 (es)
HU (1) HUE037212T2 (es)
IL (1) IL227687B (es)
LT (1) LT2672994T (es)
MX (2) MX385144B (es)
PL (1) PL2672994T3 (es)
PT (1) PT2672994T (es)
RS (1) RS57524B1 (es)
SG (1) SG192667A1 (es)
SI (1) SI2672994T1 (es)
TR (1) TR201810294T4 (es)
WO (1) WO2012107211A1 (es)
ZA (1) ZA201306807B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
SG11201702132WA (en) * 2014-09-17 2017-04-27 Merck Patent Gmbh A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
KR20170052690A (ko) 2014-09-17 2017-05-12 메르크 파텐트 게엠베하 고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
CN108473582A (zh) * 2015-11-23 2018-08-31 默克专利股份有限公司 用于治疗纤维化和/或纤维化病症的抗－αV整合素抗体
US20190144547A1 (en) 2015-11-23 2019-05-16 Merck Patent Gmbh Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
WO2024137442A1 (en) 2022-12-21 2024-06-27 Gilead Sciences, Inc. Combination therapy for treating cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1362868A3 (en) 1991-03-06 2004-02-11 MERCK PATENT GmbH Humanized and chimeric monoclonal antibodies that bind epidermal growth factor receptor (EGF-R)
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
DK0719859T3 (da) * 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
CN100404673C (zh) 2001-02-19 2008-07-23 默克专利有限公司 鉴定t细胞表位的方法及制备具有降低的免疫原性的分子的用途
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
WO2004056308A2 (en) 2002-11-26 2004-07-08 Protein Design Labs, Inc. CHIMERIC AND HUMANIZED ANTIBODIES TO α5β1 INTEGRIN THAT MODULATE ANGIOGENESIS
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
CN1953768B (zh) 2004-02-12 2010-10-13 默克专利有限公司 抗-egfr抗体的高浓缩液体制剂
KR20060002667A (ko) 2004-07-03 2006-01-09 삼성전자주식회사 디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
US8202465B2 (en) 2004-11-03 2012-06-19 Honeywell International Inc. Preferential curing technique in compression molding of fiber reinforced composites
US20070025889A1 (en) 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
EP2335733B1 (en) 2006-01-18 2014-08-06 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US8715718B2 (en) 2006-07-14 2014-05-06 Rutgers, The State University Of New Jersey Extracellular matrix production from nanoscale substrate
JP5341889B2 (ja) * 2007-07-17 2013-11-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作された抗αＶインテグリンハイブリッド抗体
WO2009026328A2 (en) 2007-08-21 2009-02-26 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
EA020764B1 (ru) 2008-12-23 2015-01-30 Мерк Патент Гмбх Биомаркеры для ингибиторов с антиангиогенной активностью
CA2771441C (en) 2009-08-19 2016-10-11 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
EA201270620A1 (ru) 2009-11-13 2012-12-28 Мерк Патент Гмбх Антитела к интегрину, связанные с наночастицами, содержащими химиотерапевтические агенты
WO2011162933A1 (en) 2010-06-04 2011-12-29 Immunogen, Inc. Anti-integrin immunoconjugate dosing regimens
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
JP6035716B2 (ja) 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles

Also Published As

Publication number Publication date
EA032117B1 (ru) 2019-04-30
CN103347540A (zh) 2013-10-09
KR102103701B1 (ko) 2020-04-23
WO2012107211A1 (en) 2012-08-16
AU2017200998A1 (en) 2017-03-09
SG192667A1 (en) 2013-09-30
JP6320042B2 (ja) 2018-05-09
TR201810294T4 (tr) 2018-08-27
MX2013009062A (es) 2013-10-01
LT2672994T (lt) 2018-07-25
AU2012216145B2 (en) 2016-11-17
SI2672994T1 (sl) 2018-09-28
HK1190094A1 (zh) 2014-06-27
JP2014510047A (ja) 2014-04-24
ES2683347T3 (es) 2018-09-26
KR101972533B1 (ko) 2019-08-26
EA201391147A1 (ru) 2014-01-30
CN103347540B (zh) 2016-05-25
RS57524B1 (sr) 2018-10-31
CA2827052A1 (en) 2012-08-16
EP3415162A1 (en) 2018-12-19
EP2672994B1 (en) 2018-05-09
CA2827052C (en) 2022-08-16
PT2672994T (pt) 2018-10-22
US20190263913A1 (en) 2019-08-29
AU2012216145A1 (en) 2013-09-26
US20170218070A1 (en) 2017-08-03
DK2672994T3 (en) 2018-07-16
ZA201306807B (en) 2014-05-28
JP2017066156A (ja) 2017-04-06
AU2017200998B2 (en) 2018-08-09
HRP20181212T1 (hr) 2018-10-05
KR20140012087A (ko) 2014-01-29
IL227687B (en) 2019-02-28
JP6488273B2 (ja) 2019-03-20
US9555110B2 (en) 2017-01-31
KR20190044696A (ko) 2019-04-30
US20140086908A1 (en) 2014-03-27
PL2672994T3 (pl) 2018-11-30
EP2672994A1 (en) 2013-12-18
HUE037212T2 (hu) 2018-08-28
IL227687A0 (en) 2013-09-30
MX352025B (es) 2017-11-07

Similar Documents

Publication Publication Date Title
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
MX2021002728A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
MX383886B (es) Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
NZ710929A (en) Antibody drug conjugates
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
NZ601580A (en) Therapeutic methods using anti-cd200 antibodies
PH12012501793B1 (en) Monoclonal antibodies against c-met
ECSP15005280A (es) Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos
EA201390506A1 (ru) Полипептиды, которые связывают компонент с5 комплемента человека
MX385144B (es) Anticuerpo anti-integrina alfa v para el tratamiento de cáncer de próstata.
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA201590359A1 (ru) Лечение ревматоидного артрита
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2025001934A (es) UN ANTICUERPO HUMANIZADO QUE TIENE ESPECIFICIDAD DE UNIÓN PARA LA INTEGRINA A4ß7 HUMANA PARA USARSE EN LA PREVENCIÓN O REDUCCIÓN DE LA APARICIÓN DE GVHD AGUDA EN UN PACIENTE HUMANO QUE TIENE ALL O AML Y QUE SE SOMETE A ALLO-HSCT